CJC-1295 with DAC Research Guide: GH, IGF-1 and Evidence

What is CJC-1295 with DAC?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC component is designed to prolong its persistence. The QRP product covered here is CJC-1295 with DAC, supplied as a 2 mg research vial. Compound identity matters: a paper on this long-acting molecule should not automatically be applied to another peptide sold under a similar name.

Potential benefits: what has actually been measured?

The clearest human finding is sustained stimulation of growth hormone (GH) and insulin-like growth factor I (IGF-1). In two randomised, placebo-controlled trials in healthy adults, researchers measured pharmacokinetics and hormone responses over short study periods. They reported increases lasting several days and evidence of accumulation with repeated exposure. These are endocrine findings, rather than proof of improved strength, injury recovery, sleep or longevity. Read the original clinical study.

Why researchers study prolonged signalling

Longer persistence allows researchers to examine how sustained GHRH-related stimulation changes the pattern of GH release. A separate investigation specifically examined pulsatile secretion during exposure to CJC-1295. This makes hormone timing and sampling important when interpreting the literature. A single hormone measurement cannot describe an entire secretion pattern. Read the pulsatility study.

What the evidence does not establish

A change in a biomarker is not automatically a health benefit. Claims about muscle gain or fat loss need studies that directly measure those outcomes, with appropriate comparison groups and meaningful follow-up. Findings in selected healthy volunteers also cannot define long-term safety in people with underlying conditions. These studies do not validate a particular commercially supplied research vial.

Safety findings and uncertainties

FDA's compounding safety assessment identifies limited clinical data and reports associated with increased heart rate and systemic vasodilatory reactions. It also raises concerns about immunogenicity and peptide impurities. Short early trials cannot settle these longer-term or product-specific questions.

Understanding the 2 mg vial and COA

The 2 mg designation describes labelled vial content, not an administration instruction. For laboratory work, match the lot number to the Certificate of Analysis and review the identity method, chromatogram and scope of testing. Chromatographic purity alone does not establish peptide content, sterility, biological potency or suitability for clinical use. The product page provides the current batch information.

QRP product and research scope

View QRP Research CJC-1295 with DAC 2 mg. This guide summarises selected research for educational purposes. QRP material is supplied for laboratory research only, not for human or veterinary administration. Laboratory handling should follow validated institutional procedures and the documentation for the actual batch.